Apr 10, 2021

TCR² Highlights Gavo-cel Translational Data and Emerging Solid Tumor Pipeline Preclinical Data at AACR Annual Meeting

Apr 08, 2021

TCR² Therapeutics to Present at the Needham Healthcare Conference

Mar 29, 2021

TCR² Therapeutics Establishes Commercial-Scale Cell Therapy Manufacturing Facility

Mar 11, 2021

TCR² Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

Mar 10, 2021

TCR² Presentations at American Association of Cancer Research (AACR) Annual Meeting 2021 to Highlight Solid Tumor Pipeline

Mar 03, 2021

TCR² Therapeutics to Participate in Two Upcoming Conferences in March

Feb 17, 2021

TCR² Therapeutics to Present at SVB Leerink Global Healthcare Conference

Feb 04, 2021

TCR² Therapeutics Announces Commercial Cell Therapy Leader Shawn Tomasello Joins its Board of Directors

Jan 19, 2021

TCR² Therapeutics Announces Pricing of Public Offering of $140.0 Million of Common Stock

Jan 19, 2021

TCR² Therapeutics Announces Proposed Public Offering of Common Stock